| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
81.89(B) |
| Last
Volume: |
7,231,910 |
Avg
Vol: |
8,754,576 |
| 52
Week Range: |
$65.27 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
3 |
5 |
9 |
14 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Manwani Harish |
Director |
• • – |
2023-05-03 |
4 |
D |
$79.45 |
$29,238 |
D/D |
(368) |
11,014 |
|
- |
|
| Manwani Harish |
Director |
• • – |
2023-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,887 |
11,382 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2023-05-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,887 |
92,653 |
|
- |
|
| Horning Sandra |
Director |
• • – |
2023-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,887 |
3,631 |
|
- |
|
| Barton Jacqueline K |
Director |
• • – |
2023-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,887 |
22,230 |
|
- |
|
| Rodriguez Javier |
Director |
• • – |
2023-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,887 |
8,392 |
|
- |
|
| Welters Anthony |
Director |
• • – |
2023-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,887 |
7,922 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2023-05-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
12,868 |
90,766 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2023-03-13 |
4 |
AS |
$78.99 |
$483,893 |
D/D |
(6,126) |
70,130 |
|
1% |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2023-03-10 |
4 |
D |
$79.50 |
$1,114,352 |
D/D |
(14,017) |
375,766 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,288 |
389,783 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2023-03-10 |
4 |
D |
$79.50 |
$423,576 |
D/D |
(5,328) |
76,256 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,454 |
81,584 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2023-03-10 |
4 |
D |
$79.50 |
$385,496 |
D/D |
(4,849) |
111,188 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,419 |
116,037 |
|
- |
|
| Patterson Sandra |
SVP, Controllership |
• • – |
2023-03-10 |
4 |
D |
$79.50 |
$63,680 |
D/D |
(801) |
26,212 |
|
- |
|
| Patterson Sandra |
SVP, Controllership |
• • – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,921 |
27,013 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2023-03-10 |
4 |
D |
$79.50 |
$406,722 |
D/D |
(5,116) |
82,225 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,976 |
87,341 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2023-03-09 |
4 |
OE |
$52.38 |
$442,192 |
D/D |
8,442 |
8,442 |
|
- |
|
| Patterson Sandra |
SVP, ControllershipOfficer |
• – – |
2023-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
24,092 |
|
-4% |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2023-03-01 |
4 |
D |
$79.59 |
$385,375 |
D/D |
(4,842) |
359,495 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,362 |
364,337 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2023-03-01 |
4 |
AS |
$79.96 |
$1,038,225 |
D/D |
(12,984) |
70,130 |
|
-4% |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2023-02-15 |
4 |
A |
$56.38 |
$21,199 |
D/D |
376 |
105,618 |
|
- |
|
2493 Records found
|
|
Page 4 of 100 |
|
|
0.31 (0.48%) 
